Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.

Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F.

Am J Surg Pathol. 1996 Jan;20(1):86-93.

PMID:
8540613
2.

Neoadjuvant hormonal therapy: the Canadian experience.

Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Bélanger A, Candas B.

Urology. 1997 Mar;49(3A Suppl):56-64.

PMID:
9123738
4.

[Effect of complete androgen block before radical prostatectomy for cancer of the prostate].

Gómez Veiga F, Lorenzo Patiño MJ, Díaz Bermúdez J, Duarte Novo J, Alvarez Castelo L, Chantada Abal V, Sánchez Rodríguez J, González Martín M.

Arch Esp Urol. 1997 May;50(4):355-63. Spanish.

PMID:
9313044
5.

The morphologic changes induced by hormone and radiation therapy on prostate carcinoma.

Roznovanu SL, Rădulescu D, Novac C, Stolnicu S.

Rev Med Chir Soc Med Nat Iasi. 2005 Apr-Jun;109(2):337-42. Review.

PMID:
16607796
8.

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.

Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS.

Cancer. 1995 Apr 1;75(7):1634-41.

9.

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.

Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.

Urology. 2000 Aug 1;56(2):289-94.

PMID:
10925096
10.

Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.

Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, et al.

Clin Invest Med. 1993 Dec;16(6):499-509.

PMID:
8013155
11.

Neoadjuvant hormonal deprivation before radical prostatectomy.

Schulman CC, Sassine AM.

Clin Invest Med. 1993 Dec;16(6):523-31.

PMID:
7516836
12.

Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.

Têtu B, Srigley JR, Boivin JC, Dupont A, Monfette G, Pinault S, Labrie F.

Am J Surg Pathol. 1991 Feb;15(2):111-20.

PMID:
1989458
14.
15.

Effects of neoadjuvant androgen deprivation therapy on prostatic cancer.

Polito M, Muzzonigro G, Minardi D, Montironi R.

Eur Urol. 1996;30 Suppl 1:26-31; discussion 38-9.

PMID:
8977987
16.

Neoadjuvant flutamide monotherapy for locally confined prostate cancer.

Yoshimura K, Sumiyoshi Y, Hashimura T, Ueda T, Kamiryo Y, Yamamoto A, Arai Y.

Int J Urol. 2003 Apr;10(4):190-5.

17.

Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.

Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G.

J Clin Pathol. 1994 Oct;47(10):906-13.

18.

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.

Van der Kwast TH, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P, Labrie F.

Prostate. 1996 Apr;28(4):227-31.

PMID:
8602398
19.

Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.

Solomon MH, McHugh TA, Dorr RP, Lee F, Siders DB.

Clin Invest Med. 1993 Dec;16(6):532-8.

PMID:
8013157
20.

Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.

Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB.

Cancer. 2000 Jan 15;88(2):407-15.

PMID:
10640975
Items per page

Supplemental Content

Write to the Help Desk